NMTR
Income statement / Annual
Last year (2022), 9 Meters Biopharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, 9 Meters Biopharma, Inc.'s net income was -$45.52 M.
See 9 Meters Biopharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.88 M
|
$4.07 M
|
$8.27 M
|
$11.34 M
|
$3.44 M
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.95 M |
$3.33 M |
$7.84 M |
$11.11 M |
$2.84 M |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$64,000.00 |
$736,000.00 |
$426,000.00 |
$234,000.00 |
$606,000.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
-0.03 |
0.18 |
0.05 |
0.02 |
0.18 |
| Research and Development
Expenses |
$31.01 M
|
$22.00 M
|
$10.93 M
|
$13.72 M
|
$7.56 M
|
$190,000.00
|
$270,000.00
|
$333,000.00
|
$542,000.00
|
$709,000.00
|
| General & Administrative
Expenses |
$11.01 M
|
$9.66 M
|
$10.52 M
|
$10.57 M
|
$10.66 M
|
$4.98 M
|
$3.98 M
|
$3.63 M
|
$2.65 M
|
$1.75 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.43 M
|
$2.43 M
|
$2.93 M
|
$3.72 M
|
$1.52 M
|
| Selling, General &
Administrative Expenses |
$11.01 M
|
$9.66 M
|
$10.52 M
|
$10.57 M
|
$10.66 M
|
$6.41 M
|
$6.41 M
|
$6.55 M
|
$6.37 M
|
$3.26 M
|
| Other Expenses |
$0.00 |
$5.10 B |
$39.42 B |
$1.27 B |
$0.00 |
$920,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$42.02 M |
$31.66 M |
$21.45 M |
$24.28 M |
$18.22 M |
$6.60 M |
$6.68 M |
$6.89 M |
$6.91 M |
$3.97 M |
| Cost And Expenses |
$42.02 M |
$31.66 M |
$21.45 M |
$24.28 M |
$18.22 M |
$8.55 M |
$10.01 M |
$14.73 M |
$18.02 M |
$6.81 M |
| Interest Income |
$501,228.00 |
$22,707.00 |
$18,992.00 |
$185,267.00 |
$163,832.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$2.67 M |
$47,188.00 |
$4.05 M |
$1.83 M |
$6.15 M |
$93,000.00 |
$825,000.00 |
$1.38 M |
$1.66 M |
$66,000.00 |
| Depreciation &
Amortization |
$509,751.00
|
$5.13 M
|
$39.46 M
|
$1.47 M
|
$19,555.00
|
$131,000.00
|
$131,000.00
|
$54,000.00
|
-$2.47 M
|
$606,000.00
|
| EBITDA |
-$41.51 M
|
-$31.63 M
|
-$21.42 M
|
-$24.08 M
|
-$18.04 M
|
-$5.62 M
|
-$5.81 M
|
-$7.30 M
|
-$9.38 M
|
-$3.37 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
-2.98 |
-1.43 |
-0.88 |
-0.83 |
-0.98 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
-4.72
|
-1.64
|
-0.83
|
-0.61
|
-1.15
|
| Total Other
Income/Expenses Net |
-$1.75 M
|
-$17,481.00
|
$60.82 B
|
-$1.50 M
|
-$5.94 M
|
$963,000.00
|
$468,000.00
|
-$1.85 M
|
-$4.13 M
|
$540,000.00
|
| Income Before Tax |
-$43.77 M |
-$36.78 M |
-$61.50 M |
-$27.05 M |
-$24.16 M |
-$7.93 M |
-$6.21 M |
-$8.74 M |
-$11.04 M |
-$3.43 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
-4.21
|
-1.53
|
-1.06
|
-0.97
|
-1
|
| Income Tax Expense |
$1.75 M |
$47,188.00 |
$4.05 M |
$1.83 M |
$213,832.00 |
$1.01 M |
$2,000.00 |
$2,000.00 |
$13,000.00 |
$4,000.00 |
| Net Income |
-$45.52 M |
-$36.83 M |
-$65.54 M |
-$28.87 M |
-$24.16 M |
-$7.93 M |
-$6.21 M |
-$8.74 M |
-$11.06 M |
-$3.44 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
-4.21 |
-1.53 |
-1.06 |
-0.97 |
-1 |
| EPS |
-3.51 |
-3.03 |
-12.41 |
-17.33 |
-19.52 |
-13.33 |
-225.11 |
-330.66 |
-416.15 |
-129.94 |
| EPS Diluted |
-3.51 |
-3.03 |
-12.41 |
-17.33 |
-19.52 |
-13.33 |
-225.11 |
-328.98 |
-416.15 |
-129.28 |
| Weighted Average Shares
Out |
$12.96 M
|
$12.16 M
|
$5.28 M
|
$1.67 M
|
$1.24 M
|
$594,412.00
|
$27,600.00
|
$26,435.00
|
$26,570.00
|
$26,435.00
|
| Weighted Average Shares
Out Diluted |
$12.96 M
|
$12.16 M
|
$5.28 M
|
$1.67 M
|
$1.24 M
|
$594,412.00
|
$27,600.00
|
$26,570.00
|
$26,570.00
|
$26,570.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
